CoChat

Efficacy of Per-oral Methylene Blue Formulation for Screening Colonoscopy

Open access
Repici, Alessandro, Wallace, Michael B., East, James E., Sharma, Prateek, Ramirez, Francisco C., Bruining, David H., Young, Michele, Gatof, David, Irene (Mimi) Canto, Marcia, Marcon, Norman, Cannizzaro, Renato, Kiesslich, Ralf, Rutter, Matt, Dekker, Evelien, Siersema, Peter D., Spaander, Manon, Kupcinskas, Limas, Jonaitis, Laimas, Bisschops, Raf, Radaelli, Franco, Bhandari, Pradeep, Wilson, Ana, Early, Dayna, Gupta, Neil, Vieth, Michael, Lauwers, Gregory Y., Rossini, Matteo, Hassan, Cesare · 2019 · Gastroenterology
Cited by 84

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

BACKGROUND & AIMS Topically applied methylene blue dye chromoendoscopy is effective in improving detection of colorectal neoplasia. When combined with a pH- and time-dependent multimatrix structure, a per-oral methylene blue formulation (MB-MMX) can be delivered directly to the colorectal mucosa. METHODS We performed a phase 3 study of 1205 patients scheduled for colorectal cancer screening or surveillance colonoscopies (50-75 years old) at 20 sites in Europe and the United States, from December 2013 through October 2016. Patients were randomly assigned to groups given 200 mg MB-MMX, placebo, or 100 mg MB-MMX (ratio of 2:2:1). The 100-mg MB-MMX group was included for masking purposes. MB-MMX and placebo tablets were administered with a 4-L polyethylene glycol-based bowel preparation. The patients then underwent colonoscopy by an experienced endoscopist with centralized double-reading. The primary endpoint was the proportion of patients with 1 adenoma or carcinoma (adenoma detection rate [ADR]). We calculated odds ratios (ORs) and 95% confidence intervals (CIs) for differences in detection between the 200-mg MB-MMX and placebo groups. False-positive (resection rate for non-neoplastic polyps) and adverse events were assessed as secondary endpoints. RESULTS The ADR was higher for the MB-MMX group (273 of 485 patients, 56.29%) than the placebo group (229 of 479 patients, 47.81%) (OR 1.46; 95% CI 1.09-1.96). The proportion of patients with nonpolypoid lesions was higher in the MB-MMX group (213 of 485 patients, 43.92%) than the placebo group (168 of 479 patients, 35.07%) (OR 1.66; 95% CI 1.21-2.26). The proportion of patients with adenomas ≤5 mm was higher in the MB-MMX group (180 of 485 patients, 37.11%) than the placebo group (148 of 479 patients, 30.90%) (OR 1.36; 95% CI 1.01-1.83), but there was no difference between groups in detection of polypoid or larger lesions. The false-positive rate did not differ significantly between groups (83 [23.31%] of 356 patients with non-neoplastic lesions in the MB-MMX vs 97 [29.75%] of 326 patients with non-neoplastic lesions in the placebo group). Overall, 0.7% of patients had severe adverse events but there was no significant difference between groups. CONCLUSIONS In a phase 3 trial of patients undergoing screening or surveillance colonoscopies, we found MB-MMX led to an absolute 8.5% increase in ADR, compared with placebo, without increasing the removal of non-neoplastic lesions. Clinicaltrials.gov no: NCT01694966.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2019.02.001

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 84

Metadata

Authors
Repici, A., Wallace, M. B., East, J. E., Sharma, P., Ramirez, F. C., Bruining, D. H., Young, M., Gatof, D., Irene (Mimi) Canto, M., Marcon, N., Cannizzaro, R., Kiesslich, R., Rutter, M., Dekker, E., Siersema, P. D., Spaander, M., Kupcinskas, L., Jonaitis, L., Bisschops, R., Radaelli, F., Bhandari, P., Wilson, A., Early, D., Gupta, N., Vieth, M., Lauwers, G. Y., Rossini, M., & Hassan, C.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2019-06
Volume
156
Issue
8
Pages
2198-2207.e1
ISSN
0016-5085 (ISSN-L)
OpenAlex
W2913899589
Cited by
84
References
2
FWCI
4.44
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of Per-oral Methylene Blue Formulation for Screening Colonoscopy. https://app.cochat.ai/papers/10.1053/j.gastro.2019.02.001
The paper
Repici, A., Wallace, M. B., East, J. E., Sharma, P., Ramirez, F. C., Bruining, D. H., Young, M., Gatof, D., Irene (Mimi) Canto, M., Marcon, N., Cannizzaro, R., Kiesslich, R., Rutter, M., Dekker, E., Siersema, P. D., Spaander, M., Kupcinskas, L., Jonaitis, L., Bisschops, R., . . . Hassan, C. (2019). Efficacy of Per-oral Methylene Blue Formulation for Screening Colonoscopy. Gastroenterology. https://doi.org/10.1053/j.gastro.2019.02.001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.